Diagnostic and Therapeutic Challenges of Malignant Pleural Mesothelioma

Malignant pleural mesothelioma is a rare cancer characterized by a very poor prognosis. Exposure to asbestos is the leading cause of malignant pleural mesothelioma. The preinvasive lesions, the mesothelial hyperplasia and its possible evolution are the focus of the majority of the studies aiming to identify the treatable phase of the disease. The role of BAP-1 and MTAP in the diagnosis of mesothelioma in situ and in the prognosis of malignant pleural mesothelioma is the main topic of recent studies. The management of preinvasive lesions in mesothelioma is still unclear and many aspects are the subject of debate. The diagnosis, the disease staging and the accurate, comprehensive assessment of patients are three key instants for an appropriate management of patients/the disease.

Automated summary

Malignant pleural mesothelioma is a rare cancer with a very poor prognosis, primarily caused by asbestos exposure. Current research focuses on identifying treatable phases of the disease, particularly preinvasive lesions and mesothelial hyperplasia. Recent studies discuss the role of BAP-1 and MTAP in diagnosing mesothelioma in situ and predicting prognosis. However, managing preinvasive lesions in mesothelioma remains unclear and controversial, including diagnosis, disease staging, and comprehensive patient assessment.